Kiora Pharmaceuticals, Inc. (KPRX)
- Previous Close
0.5055 - Open
0.5190 - Bid 0.3500 x 200
- Ask 0.6412 x 200
- Day's Range
0.4802 - 0.5198 - 52 Week Range
0.4620 - 5.2500 - Volume
156,044 - Avg. Volume
1,685,332 - Market Cap (intraday)
13.391M - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6900 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.67
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
www.kiorapharma.comRecent News: KPRX
Performance Overview: KPRX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KPRX
Valuation Measures
Market Cap
13.39M
Enterprise Value
11.04M
Trailing P/E
--
Forward P/E
1.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.54%
Return on Equity (ttm)
-142.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.04M
Diluted EPS (ttm)
-2.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.45M
Total Debt/Equity (mrq)
1.75%
Levered Free Cash Flow (ttm)
-6.77M
Research Analysis: KPRX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell